PharmacoEconomics & Outcomes News 792, p24 - 2 Dec 2017 Pharmacogenomic test cost saving in depression and anxiety The use of a pharmacogenomic test (IDgenetix) to guide treatment appears to be cost effective in patients with major depressive disorder with or without anxiety, according to findings of an AltheaDx-affiliated study published in PharmacoEconomics. A discrete-event simulation model populated with clinical trial data was used to evaluate the cost effectiveness of IDgenetix-guided treatment compared with treatment as usual in patients with moderate or severe major depressive disorder and/or anxiety, from a US societal perspective over a three-year time horizon. The assumed cost of the IDgenetix test was $2000. The predicted cumulative remission rate was 78% with the IDgenetix strategy versus 66% with usual care, and the estimated QALY gain was 2.09 and 1.94 per patient, respectively. Estimated total costs were $14 124 and $14 659, respectively, resulting in cost savings of $535 per patient in the IDgenetix group. Use of the IDgenetix test was therefore dominant (more effective and less costly) compared with usual care. QALY gains and cost savings were greater in patients with depression with or without comorbid anxiety than in those with anxiety only. Moreover the incremental QALY gain with IDgenetix was higher in patients with severe depression (+0.49) and cost savings were greater ( $6871 per patient). Sensitivity analysis showed that estimated cost savings with the IDgenetix strategy were $6000 over a 10-year time horizon and more than $10 000 over a lifetime time horizon. test on treatment "The impact of the IDgenetix efficacy is larger or, at minimum, comparable to what one might expect from a novel and effective therapeutic option," said the authors. "Overall, several features of the IDgenetix test, such as the efficacy of a guided treatment strategy, one-time test cost, and the prospect of using test results for guiding future episodes of depression or anxiety, make it a potentially dominant strategy compared with usual care," they added. * 2017 US dollars Najafzadeh M, et al. Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix(R)) to Guide Treatment of Patients with Depression and/or Anxiety. PharmacoEconomics : 6 Nov 2017. Available from: URL: http://doi.org/10.1007/s40273-017-0587-0 803283872 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera